FDA 药品质量抽样与检测强化方法(EAST)项目介绍
FDA’s Enhanced Approach for Sampling and Testing
FDA 的强化抽样与检测方法(EAST)项目通过结合快速分析技术与传统方法,扩大对美国境内外生产药品的抽样检测范围,以更早发现潜在药品质量问题。样品从零售药房和批发商处商业采购,重点评估鉴别、纯度和效价等关键质量属性,需进一步评估的样品将采用 USP 等经验证方法确认检测。项目旨在为风险评估、监管政策和检查计划提供数据支持。
Back to Drug Quality Sampling and Testing Programs
Overview
The FDA's Enhanced Approach for Sampling and Testing (EAST) proactively monitors the quality of medicines available to American patients and consumers. The program uses both faster, modern testing techniques and traditional methods to efficiently and effectively evaluate more drug products. The program supports FDA's mission by expanding sampling and testing across domestic and international manufacturing regions, enabling earlier detection of potential drug quality issues, and generating data-driven insights to inform risk-based assessment, regulatory policy, and inspection planning.
Why This Program Matters
The U.S. drug supply depends on vast networks of domestic and international manufacturers spanning multiple regions, making comprehensive quality oversight both critical and complex. Ensuring consistent drug quality across this diverse landscape requires a sensible, scalable approach to sampling and testing to allow increased direct evaluation of drug quality from global manufacturers without disrupting the availability of medicines to patients and consumers.
EAST strategically integrates rapid analysis methods and rigorous conventional techniques to increase the volume, variety and geographical origin of products evaluated. The goal is to yield a more representative view of drug quality across the American drug supply by substantially expanding surveillance coverage within the same resource constraints without compromising the analytical rigor and evidentiary standards demanded for regulatory decision-making.
Program Goals and Public Health Impact
EAST supports the FDA's mission to protect and promote public health by:
- Expanding sampling and testing across products sourced from a range of domestic and international manufacturing regions, enabling increased monitoring of drug quality across the global supply chain;
- Enabling earlier detection of potential drug quality issues and supporting timely action to reduce risks to patients;
- Providing broader surveillance coverage across more products and manufacturers than conventional methods might allow;
- Strengthening the FDA's capacity to monitor the global pharmaceutical supply chain in a resource-efficient manner;
- Generating data-driven insights to inform risk-based assessment, regulatory policy and FDA’s inspection planning.
What the Program Does
EAST conducts systematic quality evaluations of drug products marketed to American patients and consumers. Drug samples are purchased commercially from retail pharmacies and wholesale distributors, targeting the products that patients and consumers use. The agency selects products to ensure broad representation across manufacturers, therapeutic classes, and geographic regions, including both domestic and internationally manufactured drugs. The primary drug quality evaluations focus on critical quality attributes such as identity (to confirm the presence of the correct active pharmaceutical ingredient (API)), purity (to evaluate impurities), and potency (to verify the amount of the API). Additional tests may be performed if there are specific concerns about a drug product attribute.
Samples referred for further evaluation will undergo additional confirmatory testing using established, validated analytical methods, such as those described in the United States Pharmacopeia (USP). The results will be reported under the "Results" section of the FDA Drug Quality Sampling and Testing Programs.
来源:FDA 官方药品与生物制品信息 · fda.gov